ID   IPH-926
AC   CVCL_A625
SY   IPH926
DR   cancercelllines; CVCL_A625
DR   Cosmic; 1179081
DR   DSMZ; ACC-827
DR   DSMZCellDive; ACC-827
DR   GEO; GSE28089
DR   Wikidata; Q54897973
RX   PubMed=19191266;
RX   PubMed=22118813;
RX   PubMed=22945757;
RX   PubMed=24344720;
RX   PubMed=25757734;
CC   Group: Triple negative breast cancer (TNBC) cell line.
CC   Characteristics: Expresses high level of ABCB1 mRNA (PubMed=22118813).
CC   Doubling time: ~2 weeks (PubMed=19191266); 200 hours (Note=In the first 1-2 weeks), 80-120 hours (Note=After 2 weeks) (DSMZ=ACC-827).
CC   Sequence variation: Gene deletion; HGNC; 1748; CDH1; Zygosity=Heterozygous (PubMed=19191266).
CC   Sequence variation: Mutation; HGNC; 1748; CDH1; Simple; p.Val82fs*13 (c.240_241insGGTG); Zygosity=Heterozygous (PubMed=19191266).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu285Lys (c.853G>A); ClinVar=VCV000420133; Zygosity=Homozygous (PubMed=22945757).
CC   Omics: Transcriptome analysis by microarray.
CC   Derived from site: Metastatic; Ascites; UBERON=UBERON_0007795.
ST   Source(s): DSMZ=ACC-827; PubMed=22118813
ST   Amelogenin: X
ST   CSF1PO: 10,12
ST   D13S317: 11
ST   D16S539: 12
ST   D18S51: 12,22
ST   D19S433: 16
ST   D21S11: 30
ST   D2S1338: 19,20
ST   D3S1358: 15
ST   D5S818: 11
ST   D7S820: 9,11
ST   D8S1179: 13,15
ST   FGA: 19
ST   Penta D: 9
ST   Penta E: 11,12
ST   TH01: 6 (DSMZ=ACC-827)
ST   TH01: 7 (PubMed=22118813)
ST   TPOX: 8,10
ST   vWA: 15,16
DI   NCIt; C7950; Invasive breast lobular carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   72Y
CA   Cancer cell line
DT   Created: 06-06-12; Last updated: 02-05-24; Version: 15
//
RX   PubMed=19191266; DOI=10.1002/path.2495;
RA   Christgen M., Bruchhardt H., Hadamitzky C., Rudolph C., Steinemann D.,
RA   Gadzicki D., Hasemeier B., Romermann D., Focken T., Krech T.,
RA   Ballmaier M., Schlegelberger B., Kreipe H.-H., Lehmann U.;
RT   "Comprehensive genetic and functional characterization of IPH-926: a
RT   novel CDH1-null tumour cell line from human lobular breast cancer.";
RL   J. Pathol. 217:620-632(2009).
//
RX   PubMed=22118813; DOI=10.1016/j.canlet.2011.09.038;
RA   Krech T., Scheuerer E., Geffers R., Kreipe H.-H., Lehmann U.,
RA   Christgen M.;
RT   "ABCB1/MDR1 contributes to the anticancer drug-resistant phenotype of
RT   IPH-926 human lobular breast cancer cells.";
RL   Cancer Lett. 315:153-160(2012).
//
RX   PubMed=22945757; DOI=10.1038/labinvest.2012.126;
RA   Christgen M., Noskowicz M., Heil C., Schipper E., Christgen H.,
RA   Geffers R., Kreipe H.-H., Lehmann U.;
RT   "IPH-926 lobular breast cancer cells harbor a p53 mutant with
RT   temperature-sensitive functional activity and allow for profiling of
RT   p53-responsive genes.";
RL   Lab. Invest. 92:1635-1647(2012).
//
RX   PubMed=24344720; DOI=10.1111/cas.12276;
RA   Christgen M., Geffers R., Kreipe H.-H., Lehmann U.;
RT   "IPH-926 lobular breast cancer cells are triple-negative but their
RT   microarray profile uncovers a luminal subtype.";
RL   Cancer Sci. 104:1726-1730(2013).
//
RX   PubMed=25757734; DOI=10.1186/s13058-015-0517-z;
RA   Christgen M., Derksen P.W.B.;
RT   "Lobular breast cancer: molecular basis, mouse and cellular models.";
RL   Breast Cancer Res. 17:16.1-16.9(2015).
//